BOULDER, Colo., June 15, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (“CF”), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at the JMP Securities Life Sciences Conference.
Details of the presentations are as follows:
JMP Securities Life Sciences Conference
Date: Wednesday, June 22nd
Location: The St. Regis New York, New York
Presentation Time: 12:30 PM EDT
Individuals may access a live webcast of the conference presentations on the Nivalis website at www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical-stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Source:Nivalis Therapeutics, Inc.